ACC: XARELTO Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease

 — Phase 3 VOYAGER PAD is the first investigational study in 20 years to highlight the benefit of long-term treatment in these high-risk patients

— Data add to growing body of evidence on the role of dual pathway inhibition in targeting both thrombin generation and platelets

 The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO^® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO^® plus aspirin reduced first events by 15 percent among patients with PAD after LER. This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years. These data were presented as a late-breaking presentation during the virtual American College of Cardiology’s 70^th Annual Scientific Session (ACC.21) and simultaneously published in the Journal of the American College of Cardiology. 

https://www.pharmalive.com/data-show-xarelto-plus-aspirin-significantly-reduced-total-ischemic-events-in-pad-patients-after-lower-extremity-revascularization/